Home/Products /brinzolamide-ip-10mg-brimonidine-2mg-benzalkonium-chloride-0-01-w-v-eye-drop

Monopoly Rights for Brinzolamide Brimonidine Combo

Name: Brinzolamide 1% + Brimonidine 0.2% Eye Drop Franchise
Brand: Optibrinz B Eye Drop
Rating: 4.8 (150 reviews)

Maximize Profit from High-Value Glaucoma Market

Optibrinz B Edge: Fixed-Dose for Superior Compliance

Secure Exclusive Territory in Super-Specialty Segment

Low Investment, Full Technical Marketing Support

Start Your Premium Ophthalmic Business Today

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Brinzolamide Brimonidine Franchise in Delhi NCR

Glaucoma PCD opportunity for Optibrinz B in Pune

Monopoly rights Fixed Dose Ophthalmic in Karnataka

Specialty eye drop pharma franchise in Chennai

Top PCD business for Brinzolamide drops in Hyderabad

Brinzolamide Brimonidine PCD Franchise Literature PDF

Optibrinz B Eye Drop

Composition : Brinzolamide (1% w/v) + Brimonidine (0.2% w/v) Eye Drop

Dosage Form : Eye drop

Packaging Type : Dropper

Packaging : 5ml

Price : ₹0/-

Please Contact For Best Price

Optibrinz B Eye Drop (Brinzolamide 1% + Brimonidine 0.2%) is a premium, high-profit chronic care product built for our PCD Pharma Franchise partners.

This fixed-dose combination (FDC) provides two powerful mechanisms to reduce Intraocular Pressure (IOP)—a Carbonic Anhydrase Inhibitor (Brinzolamide) and an Alpha Agonist (Brimonidine). This makes it essential for patients requiring maximal IOP reduction and ensures superior compliance.

Why Optibrinz B is Your Key to Profit:

Guaranteed Recurring Revenue: Glaucoma requires lifelong treatment with FDCs being the preferred choice for compliance. This ensures stable, long-term prescription refills and excellent financial stability.
Superior Clinical Value: The FDC reduces the total number of drops a patient uses daily. This improved patient compliance is a major selling point for ophthalmologists and drives consistent prescription volume.
Maximum Specialty Margin: Positioned as a specialized FDC in the ophthalmic segment, this product commands premium pricing and secures some of the highest profit margins in the chronic care niche.
Monopoly Opportunity: We offer exclusive rights for your area—meaning zero competition in your designated super-specialty territory. Partner with us for full marketing support to secure high-value prescriptions and guaranteed business growth.

Contact us today to capture this high-margin specialty segment!

About the Product

Optibrinz B Eye Drop (Brinzolamide 1% + Brimonidine 0.2%) is a premium, high-profit chronic care product built for our PCD Pharma Franchise partners.

Why Optibrinz B is Your Key to Profit:

Guaranteed Recurring Revenue: Glaucoma requires lifelong treatment with FDCs being the preferred choice for compliance. This ensures stable, long-term prescription refills and excellent financial stability.
Superior Clinical Value: The FDC reduces the total number of drops a patient uses daily. This improved patient compliance is a major selling point for ophthalmologists and drives consistent prescription volume.
Maximum Specialty Margin: Positioned as a specialized FDC in the ophthalmic segment, this product commands premium pricing and secures some of the highest profit margins in the chronic care niche.
Monopoly Opportunity: We offer exclusive rights for your area—meaning zero competition in your designated super-specialty territory. Partner with us for full marketing support to secure high-value prescriptions and guaranteed business growth.

Contact us today to capture this high-margin specialty segment!

Patients may experience injection site discomfort, gastrointestinal upset (nausea, vomiting, diarrhea), rash, or mild liver enzyme elevations. Less commonly, hypersensitivity reactions and hematologic abnormalities such as eosinophilia or neutropenia may occur. Rare instances of C. difficile-associated diarrhea should be considered during prolonged use.

This formulation is used in the treatment of severe systemic infections such as urinary tract infections, lower respiratory tract infections (including pneumonia), intra-abdominal infections, skin and soft tissue infections, gynecological infections, and septicemia caused by susceptible gram-negative bacteria. It is particularly valuable in hospital-acquired infections or polymicrobial infections when used in combination with other antimicrobials.

This injection should only be used under the supervision of a qualified healthcare professional. Renal function should be monitored in long-term or high-dose treatments, and dose adjustment may be required in renal impairment. Aztreonam is not effective against gram-positive or anaerobic organisms, and should be used in combination therapy if mixed infections are suspected.

Store in a cool, dry place below 25°C, protected from direct sunlight. Keep the bottle tightly closed and out of reach of children.